Sanofi SA (ADR)(NYSE: SNY) stock fell 2.2% (as of 27 Apr, 1:44 PM GMT-4; source: google finance). The first-quarter 2018 IFRS earnings per share fell 82% to €0.81 due to a gain on disposal of the Animal Health business in 2017. SNY continues to expect 2018 Business earnings per share to grow in the range of 2% and 5% at CER(7) barring unforeseen major adverse events. Applying the average April 2018 exchange rates, the currency impact on 2018 Business earnings per share is estimated to be around -7%.

On the other hand, the group reported a €1.5bn share buyback program is expected to be completed in mid-2019. Further, SNY has strengthened leadership in Specialty Care through the addition of a Rare Blood Disorder franchise.

SNY in the first quarter of FY 18 has reported the adjusted earnings per share of $0.79, beating the analysts’ estimates for the adjusted earnings per share of $0.74. The company had reported 8.7 percent fall in the adjusted revenue to $7.90 billion in the first quarter of FY 18, beating the analysts’ estimates for revenue of $7.88 billion.

Moreover, in the first quarter 2018, Sanofi Genzyme sales grew strongly, which is up 16.2%, due to the contribution from the new immunology franchise. Vaccines sales fell 0.9% but reflected strong performance in EU, offset by expected Pentaxim supply constraint in China. CHC sales rose 2.0% due to the double-digit growth in Emerging Markets. However, in the first quarter 2018, Diabetes and Cardiovascular GBU sales down 15.7% and global Diabetes franchise sales fell 10.0%. Emerging Markets sales has grown 8.3%, driven by double-digit growth in China and Latin America

The first-quarter 2018 business earnings per share has increased 1.4% at CER to €1.28

Additionally, during the first quarter 2018, SNY has completed the acquisition of Bioverativ and consolidated its financial results from March 9. The first patient has been dosed with fitusiran, which is a novel RNAi therapeutic for hemophilia, in phase 3 ATLAS program. Further, Ablynx acquisition will add caplacizumab for aTTP(10) (submitted in EU) and innovative Nanobody platform.

In addition, Dupixent supplemental BLA is filed in the U.S., Japan and EU for moderate-to-severe asthma in adults and adolescents. Cemiplimab has been filed in EU for metastatic cutaneous squamous cell carcinoma and Sotagliflozin submitted in the U.S. and EU for type 1 diabetes.